• Login
    View Item 
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda.

    Thumbnail
    View/Open
    Article (395.3Kb)
    Date
    2009-11-04
    Author
    Nawaz, Fatima
    Nsobya, Samuel L.
    Kiggundu, Moses
    Joloba, Moses
    Rosenthal, Philip J.
    Metadata
    Show full item record
    Abstract
    Background. Amodiaquine (AQ) is paired with artesunate (AS) or sulfadoxine-pyrimethamine (SP) in recommended antimalarial regimens. It is unclear how readily AQ resistance will be selected with combination chemotherapy. Methods. We collected 61 Plasmodium falciparum samples from a cohort of Ugandan children randomized for treatment with AQ-SP, AS-AQ, or artemether-lumefantrine (AL) for uncomplicated malaria. In vitro susceptibility to monodesethylamodiaquine (MDAQ) was measured with a histidine-rich protein 2–based enzyme-linked immunosorbent assay, and potential resistance-mediating polymorphisms in pfmdr1 were evaluated. Results. Parasites collected from patients treated with AQ-SP or AS-AQ within the prior 12 weeks were less susceptible to MDAQ (np18; mean of the median inhibitory concentration [IC50], 62.9 nmol/L; range, 12.7–158.3 nmol/L) than were parasites from those not treated within 12 weeks ( ; mean IC50np43 , 37.5 nmol/L; range,6.3–184.7 nmol/L; Pp.009) or only from those patients in the treatment arm that did not receive AQ (np20;mean IC50, 28.8 nmol/L; range, 6.3–121.8 nmol/L; Pp.004). The proportion of strains with polymorphisms expected to mediate diminished response to AQ (pfmdr1 86Y and 1246Y) increased after AQ therapy, although differences were not statistically significant. Conclusions. Prior therapy selected for diminished response to MDAQ, which suggests that AQ-containing regimens may rapidly lose efficacy in Africa. The mechanism of diminished MDAQ response is not fully explained by known mutations in pfmdr1.
    URI
    DOI: 10.1086/647988
    http://hdl.handle.net/10570/964
    Collections
    • School of Health Sciences (Health-Sciences) Collections

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of Mak IRCommunities & CollectionsTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy TypeThis CollectionTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy Type

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV